Karins Forsberg obtained her medical from Umeå University. Her doctoral thesis was titled ”Misfolded superoxide dismutase-1 in sporadic and familial amyotrophic lateral sclerosis”. She also held a research position for 1 year at Ulm University in Germany. She is a resident in Neurology, but divides her time equally between the clinic and doing research. She is part of the multidisciplinary Clinical Care ALS Team at Umeå University Hospital. Her research concentrates on brain anatomy and pathological studies on patients carrying different ALS mutations with focus on the SOD1 protein.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.